Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Multigene Panel Testing Identifies Actionable Germline Mutations in Newly Diagnosed Endometrial Cancer

November 26th 2021

Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.

Dr. Ganesan on Leveraging Precision Medicine to Improve Cancer Care

November 22nd 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

Dr. Albitar on the Importance of Obtaining Genomic Testing in Oncology

November 3rd 2021

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

FDA Grants Partial Recognition to Memorial Sloan Kettering’s OncoKB Database

November 3rd 2021

The Food and Drug Administration has granted recognition to a partial listing of the Oncology Knowledge Base, a comprehensive precision oncology knowledge databased developed by investigators and physicians at Memorial Sloan Kettering Cancer Center.

Genomically-Guided Radiation Dosing Model Shows Promise in Various Cancer Types

November 3rd 2021

Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.

Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across Cancers

November 2nd 2021

Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations

October 27th 2021

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

FDA Greenlights Companion Diagnostic for Adjuvant Abemaciclib Plus Endocrine Therapy in High-Risk Early Breast Cancer

October 14th 2021

The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.

Novel Drug Sparks Hope for Targeting HER3 in NSCLC and Beyond

October 11th 2021

Patritumab deruxtecan, a novel antibody-drug conjugate, is emerging as a promising HER3-directed therapy in patients with non–small cell lung cancer and perhaps other solid malignancies.

Addressing AYA Cancer Requires a Tailored Approach to Practice

October 8th 2021

Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.

Key Advances Showcase the Potential of Precision Medicine in NSCLC

October 5th 2021

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

October 4th 2021

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.

Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?

September 30th 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

September 20th 2021

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.